NordicPRO-C3™ in Tumor Fibrosis
A liquid biopsy enabling the identification of cancer patients for clinical trial enrichment and patient stratification.
Figure 1. Cancer patients can have high or low nordicPRO-C3™ levels | Patient stratification and enrichment strategies have emerged as a crucial approaches to enhance the success rate of cancer drug development. In this context, cancer patients exhibit varying levels of nordicPRO-C3™, which plays a significant role in determining their treatment outcomes. Patients can be categorized into two distinct groups based on their nordicPRO-C3™ levels (Figure 1.) Inquire more about nordicPRO-C3™! |
Higher levels of nordicPRO-C3™ in cancer patients are linked to poor survival outcomes (Figure 2.) This underscores the importance of identifying patients' nordicPRO-C3™ levels as part of patient stratification and enrichment strategies, as it can significantly impact treatment decisions and ultimately improve the effectiveness of cancer therapies. By tailoring treatments based on nordicPRO-C3™ levels, healthcare professionals can target the right therapies to the right patients, offering them a better chance at successful outcomes in their battle against cancer. |  Figure 2. High levels of nordicPRO-C3™ associate with poor survival outcome |
Clinical Relevance (Mode-of-Action):
NordicPRO-C3™ can contribute to a better understanding of tumor fibrosis, disease progression, and response to treatment.
Diagnostic Value:
NordicPRO-C3™ can diagnose the presence of active fibrotic disease in patients with solid tumors.
Prognostic Value:
NordicPRO-C3™ predicts the course of the disease (prognosis) and the likelihood of relapse, progression, and mortality.
Treatment Guidance (Prediction of Response):
NordicPRO-C3™ can guide treatment decisions and assist in selecting the most effective treatment options for patients.
Monitoring (Pharmaco-dynamics):
NordicPRO-C3™ can be used to track the progression of a disease or the effectiveness of treatment over time
Cost-Effectiveness:
NordicPRO-C3™ can lead to cost savings by preventing unnecessary treatments and increasing the chance of meeting endpoints.
Comparison with Existing Methods:
NordicPRO-C3™ is measured non-invasively in serum/plasma (liquid biopsy) and reduces the need for tissue biopsies.
Regulatory Considerations:
NordicPRO-C3™ can be measured on the Roche Diagnostics cobas® e platform enabling future in-vitro diagnostic (IVD) use.[1]
[1] The current Elecsys® NordicPRO-C3™prototype assay from Roche Diagnostics is presently intended for research use only in exploratory studies. Not for use in diagnostic procedures.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
